Abstract

PIP: 10 years' clinical experience with Rh immune globulin in the prevention of Rh hemolytic disease is reported. The data show a steady decline in the actual numbers of sensitized mothers and affected babies for each successive year after the initiation of treatment with Rh immune globulin. It is concluded that all Rh-negative women who are at any risk of becoming sensitized to Rh must be protected with Rh immune globulin irrespective of whether they have had a term pregnancy (Rh-positive infant), an abortion or an accidental transfusion with Rh-positive blood.